FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W180946569> ?p ?o ?g. }

• W180946569 endingPage "153" @default.
• W180946569 startingPage "145" @default.
• W180946569 abstract "Angiotensin-converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure. We assessed the role of an angiotensin-converting-enzyme inhibitor, ramipril, in patients who were at high risk for cardiovascular events but who did not have left ventricular dysfunction or heart failure.A total of 9297 high-risk patients (55 years of age or older) who had evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure were randomly assigned to receive ramipril (10 mg once per day orally) or matching placebo for a mean of five years. The primary outcome was a composite of myocardial infarction, stroke, or death from cardiovascular causes. The trial was a two-by-two factorial study evaluating both ramipril and vitamin E. The effects of vitamin E are reported in a companion paper.A total of 651 patients who were assigned to receive ramipril (14.0 percent) reached the primary end point, as compared with 826 patients who were assigned to receive placebo (17.8 percent) (relative risk, 0.78; 95 percent confidence interval, 0.70 to 0.86; P<0.001). Treatment with ramipril reduced the rates of death from cardiovascular causes (6.1 percent, as compared with 8.1 percent in the placebo group; relative risk, 0.74; P<0.001), myocardial infarction (9.9 percent vs. 12.3 percent; relative risk, 0.80; P<0.001), stroke (3.4 percent vs. 4.9 percent; relative risk, 0.68; P<0.001), death from any cause (10.4 percent vs. 12.2 percent; relative risk, 0.84; P=0.005), revascularization procedures (16.3 percent vs. 18.8 percent; relative risk, 0.85; P<0.001), cardiac arrest (0.8 percent vs. 1.3 percent; relative risk, 0.62; P=0.02), [corrected] heart failure (9.1 percent vs. 11.6 percent; relative risk, 0.77; P<0.001), and complications related to diabetes (6.4 percent vs. 7.6 percent; relative risk, 0.84; P=0.03).Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure." @default.
• W180946569 created "2016-06-24" @default.
• W180946569 creator A5018419311 @default.
• W180946569 creator A5039145780 @default.
• W180946569 creator A5047726859 @default.
• W180946569 creator A5078471246 @default.
• W180946569 creator A5080331146 @default.
• W180946569 creator A5090093329 @default.
• W180946569 date "2000-01-20" @default.
• W180946569 modified "2023-10-16" @default.
• W180946569 title "Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients" @default.
• W180946569 cites W113714250 @default.
• W180946569 cites W1966953116 @default.
• W180946569 cites W1980000060 @default.
• W180946569 cites W2001212657 @default.
• W180946569 cites W2046942614 @default.
• W180946569 cites W2064099037 @default.
• W180946569 cites W2066187800 @default.
• W180946569 cites W2102979143 @default.
• W180946569 cites W2137408480 @default.
• W180946569 cites W2138670606 @default.
• W180946569 cites W2139480984 @default.
• W180946569 cites W2157734027 @default.
• W180946569 cites W2312388685 @default.
• W180946569 cites W2326354230 @default.
• W180946569 cites W2469805673 @default.
• W180946569 cites W2615684303 @default.
• W180946569 cites W4230893588 @default.
• W180946569 cites W4239471829 @default.
• W180946569 doi "https://doi.org/10.1056/nejm200001203420301" @default.
• W180946569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10639539" @default.
• W180946569 hasPublicationYear "2000" @default.
• W180946569 type Work @default.
• W180946569 sameAs 180946569 @default.
• W180946569 citedByCount "7924" @default.
• W180946569 countsByYear W1809465692012 @default.
• W180946569 countsByYear W1809465692013 @default.
• W180946569 countsByYear W1809465692014 @default.
• W180946569 countsByYear W1809465692015 @default.
• W180946569 countsByYear W1809465692016 @default.
• W180946569 countsByYear W1809465692017 @default.
• W180946569 countsByYear W1809465692018 @default.
• W180946569 countsByYear W1809465692019 @default.
• W180946569 countsByYear W1809465692020 @default.
• W180946569 countsByYear W1809465692021 @default.
• W180946569 countsByYear W1809465692022 @default.
• W180946569 countsByYear W1809465692023 @default.
• W180946569 crossrefType "journal-article" @default.
• W180946569 hasAuthorship W180946569A5018419311 @default.
• W180946569 hasAuthorship W180946569A5039145780 @default.
• W180946569 hasAuthorship W180946569A5047726859 @default.
• W180946569 hasAuthorship W180946569A5078471246 @default.
• W180946569 hasAuthorship W180946569A5080331146 @default.
• W180946569 hasAuthorship W180946569A5090093329 @default.
• W180946569 hasBestOaLocation W1809465691 @default.
• W180946569 hasConcept C126322002 @default.
• W180946569 hasConcept C127413603 @default.
• W180946569 hasConcept C134018914 @default.
• W180946569 hasConcept C142724271 @default.
• W180946569 hasConcept C164705383 @default.
• W180946569 hasConcept C204787440 @default.
• W180946569 hasConcept C27016395 @default.
• W180946569 hasConcept C27081682 @default.
• W180946569 hasConcept C2778198053 @default.
• W180946569 hasConcept C2779611605 @default.
• W180946569 hasConcept C2779888176 @default.
• W180946569 hasConcept C2780645631 @default.
• W180946569 hasConcept C44249647 @default.
• W180946569 hasConcept C500558357 @default.
• W180946569 hasConcept C555293320 @default.
• W180946569 hasConcept C71924100 @default.
• W180946569 hasConcept C78085059 @default.
• W180946569 hasConcept C78519656 @default.
• W180946569 hasConcept C82789193 @default.
• W180946569 hasConcept C84393581 @default.
• W180946569 hasConceptScore W180946569C126322002 @default.
• W180946569 hasConceptScore W180946569C127413603 @default.
• W180946569 hasConceptScore W180946569C134018914 @default.
• W180946569 hasConceptScore W180946569C142724271 @default.
• W180946569 hasConceptScore W180946569C164705383 @default.
• W180946569 hasConceptScore W180946569C204787440 @default.
• W180946569 hasConceptScore W180946569C27016395 @default.
• W180946569 hasConceptScore W180946569C27081682 @default.
• W180946569 hasConceptScore W180946569C2778198053 @default.
• W180946569 hasConceptScore W180946569C2779611605 @default.
• W180946569 hasConceptScore W180946569C2779888176 @default.
• W180946569 hasConceptScore W180946569C2780645631 @default.
• W180946569 hasConceptScore W180946569C44249647 @default.
• W180946569 hasConceptScore W180946569C500558357 @default.
• W180946569 hasConceptScore W180946569C555293320 @default.
• W180946569 hasConceptScore W180946569C71924100 @default.
• W180946569 hasConceptScore W180946569C78085059 @default.
• W180946569 hasConceptScore W180946569C78519656 @default.
• W180946569 hasConceptScore W180946569C82789193 @default.
• W180946569 hasConceptScore W180946569C84393581 @default.
• W180946569 hasIssue "3" @default.
• W180946569 hasLocation W1809465691 @default.
• W180946569 hasLocation W1809465692 @default.

• next